Edition:
United States

Aralez Pharmaceuticals Inc (ARZ.TO)

ARZ.TO on Toronto Stock Exchange

2.94CAD
24 Mar 2017
Change (% chg)

$-0.02 (-0.68%)
Prev Close
$2.96
Open
$3.00
Day's High
$3.03
Day's Low
$2.88
Volume
26,251
Avg. Vol
21,718
52-wk High
$8.75
52-wk Low
$2.77

Latest Key Developments (Source: Significant Developments)

Aralez CEO purchases 500,000 shares of company common stock on open market
Monday, 20 Mar 2017 06:30am EDT 

Aralez Pharmaceuticals Inc : Aralez Pharmaceuticals- Adrian Adams, CEO, acquired additional 500,000 shares of company's common stock on March 15, 2017 in open-market purchases . Aralez Pharmaceuticals - shares were purchased at an average price of $2.46 per share, for an aggregate purchase price of approximately $1.2 million .Adams now owns about 3.6 million shares of company's common stock.  Full Article

Aralez Pharmaceuticals reports Q4 loss per share $0.48
Monday, 13 Mar 2017 06:30am EDT 

Aralez Pharmaceuticals Inc : Aralez reports fourth quarter and full-year 2016 financial results . Qtrly net revenues increased to $20 million versus $6 million in comparable period of 2015 . Sees 2017 net revenues to be in a range of $80 million to $100 million . Aralez Pharmaceuticals Inc qtrly loss per share $0.48 .Sees 2017 adjusted EBITDA to be in a range of a loss of $25 million to a loss of $10 million.  Full Article

Aralez provides update on PBM formulary status for Yosprala
Monday, 9 Jan 2017 06:00am EST 

Aralez Pharmaceuticals Inc : Aralez provides update on PBM formulary status for Yosprala . Entered into a rebate agreement with Express Scripts Inc., which secures formulary status for Yosprala .Rebate agreement with Express Scripts became effective January 1, 2017.  Full Article

Aralez Q2 GAAP loss per share $0.27
Tuesday, 9 Aug 2016 08:00am EDT 

Aralez Pharmaceuticals Inc : Aralez reports second quarter 2016 financial results . Q2 revenue $12.6 million versus $5.2 million . Q2 GAAP loss per share $0.27 .Q2 earnings per share view $-0.22, revenue view $11.9 million -- Thomson Reuters I/B/E/S.  Full Article

Aralez posts Q1 loss of $0.73/share
Tuesday, 10 May 2016 07:29am EDT 

Aralez Pharmaceuticals Inc : Aralez reports first quarter 2016 financial results . Qtrly GAAP loss per share $0.73 .Total net revenues for three months ended March 31, 2016 were about $8.1 million compared to $4.4 million.  Full Article

Aralez Pharmaceuticals receives Health Canada approval For BLEXTEN
Monday, 25 Apr 2016 07:00am EDT 

Aralez Pharmaceuticals:Says Health Canada approval of BLEXTEN for treatment of symptoms of seasonal allergic rhinitis and chronic spontaneous urticaria.BLEXTEN will be distributed in Canada by Tribute Pharmaceuticals Canada Inc, also a subsidiary of Company.  Full Article

More From Around the Web

No consensus analysis data available.